Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase II Clinical Study to Evaluate the Efficacy and Safety of KX-826 Tincture in the Treatment of Adult Male Androgenetic Alopecia (AGA) Patients in China

Next Previous
Trial Profile

A Phase II Clinical Study to Evaluate the Efficacy and Safety of KX-826 Tincture in the Treatment of Adult Male Androgenetic Alopecia (AGA) Patients in China

Status: Completed
Phase of Trial: Phase II

Latest Information Update: 16 Aug 2025

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Pyrilutamide (Primary)
  • Indications Alopecia
  • Focus Registrational; Therapeutic Use
  • Sponsors Suzhou Kintor Pharmaceuticals

Most Recent Events

  • 25 Jul 2025 According to Kintor Pharmaceutical Limited media release, the analysis results were reviewed by the Independent Data Monitoring Committee (IDMC), and its primary recommendation was that the Phase III Stage clinical trial should continue based on the current safety and efficacy data, with no modifications to treatment group or sample size.
  • 25 Jul 2025 Results presented in Kintor Pharmaceutical Limited media release.
  • 25 Jul 2025 Primary endpoint has been met. (change in non-vellus hair count in the target area (TAHC, mean change from baseline at Week 24))

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top